Neuland Laboratories · NSE: NEULANDLAB · BSE: 524558
Q2 FY21 results · Jul–Sep 2020
Neuland Laboratories reported revenue from operations of ₹241.39 crore (up 29.6% from Q2 FY20) and net profit of ₹21.44 crore (up 146.8% from Q2 FY20) for Q2 FY21 (Jul–Sep 2020), on a consolidated basis.
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 241.39 | 186.22 | +29.6% | 205.42 | +17.5% |
| Other income | 0.61 | 0.57 | +6.4% | 0.70 | −13.1% |
| Total income | 242.00 | 186.79 | +29.6% | 206.12 | +17.4% |
| Profit before tax | 28.69 | 12.45 | +130.3% | 20.31 | +41.2% |
| Net profit for the period | 21.44 | 8.69 | +146.8% | 15.16 | +41.4% |
| EPS, basic (₹) | 16.71 | 6.77 | +146.8% | 11.82 | +41.4% |
| Net margin (%) | 8.9 | 4.7 | 7.4 |
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 241.39 | 186.21 | +29.6% | 205.42 | +17.5% |
| Other income | 0.61 | 0.57 | +6.3% | 0.70 | −13.1% |
| Total income | 242.00 | 186.78 | +29.6% | 206.12 | +17.4% |
| Profit before tax | 28.58 | 12.33 | +131.8% | 20.20 | +41.5% |
| Net profit for the period | 21.34 | 8.57 | +149.1% | 15.06 | +41.7% |
| EPS, basic (₹) | 16.63 | 6.68 | +149.0% | 11.74 | +41.7% |
| Net margin (%) | 8.8 | 4.6 | 7.3 |
Consolidated
- Filed with BSE
- 09 Nov 2020, 12:17 IST
- Board meeting
- 03 Nov 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 09 Nov 2020, 12:17 IST
- Board meeting
- 03 Nov 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE